4DMedical shares (ASX:4DX) have shown some strong price volatility in recent sessions, with today marking the third session in four that the share price has moved double digit percentages. The respiratory imaging technology company’s shares continues to be actively traded as markets digest the latest strategic announcements and financial updates.
Today, 4DMedical shares closed at A$4.69, marking an 11.93% increase, and making the shares the second best performer on the ASX 200. This surge follows several sessions of double-digit percentage moves, reflecting heightened market sensitivity to the company’s news flow.
The latest catalyst for this upward movement is the announcement of a commercial agreement with UC San Diego Health. UC San Diego Health, a leading academic health system consistently ranked in the top 10 for Pulmonology & Lung Surgery in the United States, has initiated clinical use of 4DMedical’s CT:VQ technology under a structured launch framework, which includes introductory pricing through March 31.
4DMedical’s CEO and founder, Andreas Fouras, commented on the agreement, stating, “UCSD is consistently ranked in the top 10 for pulmonology & lung surgery and is home to a world-class cardiothoracic imaging program. Their adoption of CT:VQ represents another powerful validation of our technology and our strategic approach to commercialisation.”
This news follows an earlier significant event in December 2025, when 4DMedical expanded its distribution agreement with Koninklijke Philips for the CT:VQ imaging solution. The partnership includes a minimum customer order commitment of approximately US$10 million over 2026 and 2027, with Philips distributing CT:VQ through its North American network. The markets reacted positively to this development, with 4DMedical’s shares rising by 28.4% following the announcement.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Further bolstering market confidence, in July 2025, 4DMedical secured a $10 million strategic investment from Pro Medicus, structured as a hybrid debt and equity loan. The investment is intended to accelerate 4DMedical’s commercial pipeline and advance CT:VQ towards U.S. regulatory clearance.
In September 2025, 4DMedical achieved a crucial regulatory milestone, receiving FDA 510(k) clearance and CMS reimbursement confirmation for CT:VQ. This clearance enables clinical use and reimbursement in the U.S., significantly expanding the technology’s market potential and contributing to a 44.3% increase in the share price at the time.
Financially, 4DMedical reported operating revenue of $5.9 million for the fiscal year ending June 30, 2025, a 56% increase from the previous year, with gross margins exceeding 90%. The company also secured $22.6 million through the exercise of options, bringing its cash balance to $45.5 million as of October 3, 2025.
The recent volatility in 4DMedical’s share price reflects a combination of positive catalysts and inherent risks associated with a growth-stage medical technology company. The commercial agreement with UC San Diego Health, the expanded partnership with Philips, strategic investment from Pro Medicus, and FDA clearance all point to positive momentum. However, the company’s future performance will depend on its ability to successfully execute its commercialization strategy and achieve widespread adoption of its CT:VQ technology.
